Compare Enveric Biosciences Inc (ENVB) vs Altria Group Inc (MO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Altria Group Inc — how do they compare? Enveric Biosciences Inc trades at $1.39 (market cap $5.32M), while Altria Group Inc trades at $72.23 (market cap $117.76B). The key difference: Altria Group Inc is far larger — about 22135.3× Enveric Biosciences Inc's market cap, and Altria Group Inc pays a 6.01% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | MO | |
|---|---|---|
Market Cap | $5.32M | $117.76B |
Sector | Health | Consumer Staples |
52-Week High | $17.40 | $74.55 |
52-Week Low | $1.28 | $54.72 |
Enterprise Value | $408.82K | $138.83B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
MO trades at $72.14, up 2.79% today, near the consensus price target of $71.00. Technicals are bearish with support at $70 and resistance at $72. The company reported Q1 2026 EPS of $1.32, beating estimates, but Q4 2025 missed. Revenue for 2025 was $20.14B with a net income margin of 39.52%. Recent news highlights its status as a Dividend King, with a focus on high yields and defensive qualities amid market volatility.
Outlook: MO offers a high dividend yield and stable cash flow, but faces risks from declining smoking trends and regulatory pressures. Analysts are mostly bullish (61.53% buy ratings), yet technical weakness and debt levels warrant caution. The stock presents income appeal but requires monitoring of earnings consistency and sector challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
